Challenges in Testing Intranasal Ketamine in Obsessive-Compulsive Disorder

Article AbstractBecause this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.To the Editor: Given prior reports that a single intravenous (IV) dose of ketamine, a glutamate receptor modulator, rapidly decreases symptoms in unmedicated patients with obsessive-compulsive disorder (OCD), we explored whether an intranasal delivery system is a practical alternative (eg, lower cost and easier...